



## **Eleison Pharmaceuticals Partners with Intelgen (HK) Limited to Develop and Commercialize ILC for the China Market**

St. Petersburg, FL, January 19, 2015 -- Eleison Pharmaceuticals, Inc. ("Eleison"), a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced a partnership with Intelgen (HK) Limited ("Intelgen") to develop and commercialize the lung cancer drug candidate ILC (Inhaled Lipid-complexed Cisplatin) for the Chinese market. Mr. Edwin Thomas, CEO of Eleison Pharmaceuticals commented, "We are highly pleased to have as a partner Intelgen, an emerging pharmaceutical company in China and ideally capable of developing and commercializing ILC." Ms. Lan Zou, President and CEO of Intelgen commented, "ILC is potentially an important new treatment for lung cancer, and we look forward to working with Eleison to develop ILC for the benefit of patients with few therapeutic options." Under the terms of the partnership agreement, Intelgen received exclusive marketing rights in China and will be responsible for marketing and distribution of ILC in the China market. Eleison and Intelgen will work cooperatively for the clinical development and regulatory approval of ILC in China. Eleison has received an up-front payment, and will receive royalties, milestone payments, and development support from Intelgen.

### **About ILC**

Eleison has an exclusive worldwide license to ILC, a novel, sustained release formulation of cisplatin in a nanoscale lipid based complex administered via inhalation. ILC was designed to deliver high levels of sustained release cisplatin targeted to the lung, without systemic-related toxicities. Eleison is currently conducting a Phase II study of ILC in patients with pediatric osteosarcoma metastatic to the lung. In 2015, Eleison and Intelgen plan to commence a Phase II study of ILC in patients with non-small cell lung cancer ("NSCLC").

### **About Pediatric Osteosarcoma**

In the U.S., 500 children and young adults are diagnosed with osteosarcoma each year, a type of bone cancer. Standard therapy includes a combination of surgery and chemotherapy, although 30-35% of patients will experience a recurrence, most often in the lungs and only in the lungs. The prognosis for relapsed patients with pulmonary metastases is particularly grim, with five year survival of less than 25%.

### **About Non-Small Cell Lung Cancer**

NSCLC is leading cause of death by cancer in the United States and worldwide, accounting for 159,000 deaths in the U.S. and 1.6 million worldwide in 2014. Smoking is the main cause of NSCLC, but pollution is also major contributory factor.

### **About Eleison Pharmaceuticals**

Eleison's mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" oncology indications, providing new hope for patients with rare life-threatening diseases. In addition to ILC, Eleison is developing Glufosfamide, a Phase III drug candidate for the treatment of patients with pancreatic cancer, and is in discussions to acquire other promising candidates for rare cancers. Eleison was founded in 2009 and is headquartered in St. Petersburg, FL.

### **About Intelgen (HK) Limited**

Intelgen is a Hong Kong biotech and pharmaceutical company specialized in research and development of novel anticancer drugs, with subsidiaries and operations in Hong Kong and mainland China.

### **Forward Looking Statements**

Except for statements of historical fact, the statements in this news release are forward-looking statements, including statements regarding Eleison's product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such

clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

COMPANY CONTACT: Eleison Pharmaceuticals LLC  
Corporate Communications  
263 13th Avenue South, Suite 375  
St. Petersburg, FL 33701  
tel: 215-554-3530  
email: [info@eleison-pharma.com](mailto:info@eleison-pharma.com)